MedPath

Senti Biosciences, Inc.

🇺🇸United States
Ownership
-
Employees
48
Market Cap
$12.5M
Website
Introduction

Senti Biosciences, Inc. It was incorporated in Delaware on March 1, 2021. The company aims to design genetic circuits to improve the intelligence of cells and gene therapy to improve its effectiveness, accuracy and persistence in the treatment of a wide range of diseases that cannot be solved by traditional drugs. The company's synthetic biology platform uses ready-made chimeric antigen receptor natural killer cells and is equipped with these genetic circuit technologies for particularly challenging liquid and solid tumor indications. The company's leading projects include SENTI-202 and SENTI-301. SENTI-202 is a logic-gated or + non-ready-made CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia cells while preserving healthy bone marrow. SENTI-301 is an off-the-shelf CAR-NK cell therapy for the treatment of hepatocellular carcinoma. The company has also demonstrated the breadth of its genetic circuits in ways other than oncology and diseases, and has partnered with Spark and BlueRock to advance these capabilities.

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults with CD33 And/or FLT3 Blood Cancers Including AML/MDS

Phase 1
Recruiting
Conditions
AML/MDS
CD33 Expressing Hematological Malignancies
FLT3 Expressing Hematological Malignancies
Interventions
First Posted Date
2024-03-22
Last Posted Date
2025-03-30
Lead Sponsor
Senti Biosciences
Target Recruit Count
21
Registration Number
NCT06325748
Locations
🇺🇸

UCLA Medical Center, Los Angeles, California, United States

🇺🇸

Colorado Blood Cancer Institute, Denver, Colorado, United States

🇺🇸

Mayo Clinic, Jacksonville, Florida, United States

and more 5 locations

News

Senti Bio Receives $1M CIRM Milestone Payment as SENTI-202 CAR-NK Therapy Shows Promising Early Results in Blood Cancers

Senti Bio received an additional $1.0 million from the California Institute of Regenerative Medicine (CIRM) upon achieving clinical enrollment milestones for its SENTI-202 CAR-NK therapy trial.

Senti Bio's Logic-Gated CAR-NK Cell Therapy Shows Promising Results in AML Clinical Trial

Senti Biosciences presented positive preliminary data from its Phase 1 trial of SENTI-202, showing 5 of 7 evaluable patients with relapsed/refractory AML achieved objective responses, including 4 complete remissions that were all MRD-negative.

Novel "Off-the-Shelf" CAR NK Cell Therapy Shows Complete Remission in Relapsed AML Patients

SENTI-202, a first-in-class CAR NK cell therapy using innovative logic-gating technology, achieved complete remission in four of seven evaluable patients with relapsed/refractory acute myeloid leukemia.

Senti Bio Reports Promising Early Results for Gene Circuit CAR-NK Cell Therapy in Relapsed/Refractory AML

Senti Bio's SENTI-202, a gene circuit-enabled CAR-NK cell therapy, achieved MRD-negative complete remission in 2 of 3 relapsed/refractory AML patients at the lowest dose level in its Phase 1 trial, with both patients maintaining remission.

Over 120 Pipeline Therapies Target Acute Myeloid Leukemia as Research Intensifies

• DelveInsight's latest report reveals a robust pipeline with 110+ companies developing 120+ therapies for acute myeloid leukemia (AML), showing significant investment in this aggressive blood cancer. • Several promising candidates are advancing through clinical trials, including GlycoMimetics' uproleselan in Phase III, BioSight's aspacytarabine (BST-236) in Phase II, and novel approaches like Senti Biosciences' logic-gated CAR-NK cell therapy. • Recent developments include Moleculin Biotech's Phase III MIRACLE trial for annamycin, Qurient's adrixetinib IND approval, and Rigel Pharmaceuticals' trial of REZLIDHIA in combination therapy for IDH1-mutated AML.

NK Cell Therapy Market Poised for Significant Growth with Innovative Pipeline Developments

The NK cell therapy market is experiencing robust growth driven by increasing interest in immuno-oncology and advancements in cell engineering technologies, with significant expansion expected through 2034.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Š 2025 MedPath, Inc. All rights reserved.